---
title: "RNAZ.US (RNAZ.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/RNAZ.US/news.md"
symbol: "RNAZ.US"
name: "RNAZ.US"
parent: "https://longbridge.com/en/quote/RNAZ.US.md"
datetime: "2026-06-13T21:06:58.804Z"
locales:
  - [en](https://longbridge.com/en/quote/RNAZ.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/RNAZ.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/RNAZ.US/news.md)
---

# RNAZ.US (RNAZ.US) — Related News

### [Top Biotech Gainers: PBLS Soars Over 50%, CLOV Rallies On Legal Win, RNAZ, TMCI On Watch](https://longbridge.com/en/news/289404778.md)
*2026-06-11T03:09:02.000Z*
> Top biotech gainers included Parabilis (PBLS), which surged 58% following its Nasdaq IPO debut, and Clover Health (CLOV)

### [TransCode Therapeutics to Host R&D Webcast on June 18, 2026 | RNAZ Stock News](https://longbridge.com/en/news/289052490.md)
*2026-06-08T04:05:31.000Z*
> TransCode Therapeutics to Host R&D Webcast on June 18, 2026 | RNAZ Stock News

### [](https://longbridge.com/en/news/288611636.md)
*2026-06-03T16:57:18.000Z*
> TransCode Therapeutics shares are trading lower. The company announced Phase 1a dose escalation clinical trial update sh

### [Pre-Market Movers: PMI, CNTB, RNAZ Chart The Course](https://longbridge.com/en/news/288584002.md)
*2026-06-03T13:20:34.000Z*
> Pre-market biotech trading on Wednesday showed significant volatility driven by clinical updates and corporate developme

### [EXCLUSIVE: TransCode's RNA Therapeutic Achieves 64% Stable Disease Rate In Colorectal Cancer Phase 1 Study](https://longbridge.com/en/news/288573090.md)
*2026-06-03T11:41:41.000Z*
> TransCode Therapeutics announced the successful completion of its Phase 1a trial for TTX-MC138, an RNA therapeutic candi

### [TransCode Therapeutics Successfully Completes Phase 1a Clinical Trial, Reports Safety and Stabilization Data for TTX-MC138 in Metastatic Cancer | RNAZ Stock News](https://longbridge.com/en/news/288572885.md)
*2026-06-03T04:05:33.000Z*
> TransCode Therapeutics Successfully Completes Phase 1a Clinical Trial, Reports Safety and Stabilization Data for TTX-MC1